Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 4/20 | 0.46 |
| ▸ | PGR | P06401 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534396 | 0.86 | NR3C1 (0.50) | NR3C1PGRARTRPV1CLK4 | |
| SCHEMBL5399477 | 0.82 | NR3C1 (0.45) | NR3C1PGRARTRPV1 | |
| SCHEMBL3531930 | 0.81 | NR3C1 (0.51) | NR3C1PGRARTRPV1CLK4 | |
| SCHEMBL3533919 | 0.80 | NR3C1 (0.70) | NR3C1PGRARTRPV1 | |
| SCHEMBL4572881 | 0.79 | NR3C1 (0.57) | NR3C1PGRARTRPV1 | |
| SCHEMBL4572886 | 0.79 | NR3C1 (0.57) | NR3C1PGRARTRPV1 | |
| SCHEMBL3531489 | 0.79 | NR3C1 (0.57) | NR3C1PGRARTRPV1 | |
| SCHEMBL3534910 | 0.79 | NR3C1 (0.49) | NR3C1PGRARTRPV1 | |
| SCHEMBL5280871 | 0.79 | NR3C1 (0.42) | NR3C1PGRARTRPV1 | |
| SCHEMBL332322 | 0.78 | NR3C1 (0.54) | NR3C1PGRARTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863765-A1 | 6, 7, 8, 9-TETRAHYDRO-5-AMINO-5H-BENZOCYCLOHEPTEN-6-OL DERIVATIVES AND RELATED COMPOUNDS USED AS ANTI-INFLAMMATORY AGENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-12 | — | — | EP | disclosed |
| US-20060247292-A1 | Benzocycloheptene derivatives, process for their production and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-11-02 | — | — | US | disclosed |
| WO-2006100099-A1 | 6, 7, 8, 9-TETRAHYDRO-5-AMINO-5H-BENZOCYCLOHEPTEN-6-OL DERIVATIVES AND RELATED COMPOUNDS USED AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247292-A1 | Benzocycloheptene derivatives, process for their production and their use as anti-inflammatory agents | TNF, NFKBIA, PTGES | NR3C1 294/4885PGR 874/4885AR 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.